BACKGROUND: It has been proposed that, independent of the epsilon4 allele, APOE promoter polymorphisms (-491 A/T and -219 G/T) may be risks factor for Alzheimer's disease by modulating APOE expression. OBJECTIVE: To measure the level of APOE expression in Alzheimer's disease. METHODS: Brains were obtained at necropsy from 114 patients with early and late onset sporadic Alzheimer's disease in Greater Manchester (UK) during years 1986 to 2001. Total RNA was extracted from 84 brains. Purified lymphocytes were obtained from fresh blood from 16 probable Alzheimer cases from Lille (France). APOE and beta-actin gene expression was determined by reverse transcriptase polymerase chain reaction in brain and lymphocytes. RESULTS: An inverse correlation between APOE expression level and A beta loads was observed. As previously described and extended to 114 cases here, an association between the -219 TT genotype and a higher level of parenchymal A beta deposition was found, irrespective of APOE epsilon4 allele status. This effect was more pronounced in older individuals, whereas higher A beta load appeared more closely related to epsilon4 in the younger age group (cut off point at the median age at death (72.5 years)). The -219 TT genotype was associated with a decrease in APOE expression. There was a 60% decrease in APOE expression in lymphocytes from probable Alzheimer cases v controls (p = 0.01). CONCLUSIONS: In the oldest individuals, reduced APOE expression, modulated in part by -219 G/T polymorphism, may influence risk and constitute a determinant A beta load in Alzheimer's disease.
BACKGROUND: It has been proposed that, independent of the epsilon4 allele, APOE promoter polymorphisms (-491 A/T and -219 G/T) may be risks factor for Alzheimer's disease by modulating APOE expression. OBJECTIVE: To measure the level of APOE expression in Alzheimer's disease. METHODS: Brains were obtained at necropsy from 114 patients with early and late onset sporadic Alzheimer's disease in Greater Manchester (UK) during years 1986 to 2001. Total RNA was extracted from 84 brains. Purified lymphocytes were obtained from fresh blood from 16 probable Alzheimer cases from Lille (France). APOE and beta-actin gene expression was determined by reverse transcriptase polymerase chain reaction in brain and lymphocytes. RESULTS: An inverse correlation between APOE expression level and A beta loads was observed. As previously described and extended to 114 cases here, an association between the -219 TT genotype and a higher level of parenchymal A beta deposition was found, irrespective of APOE epsilon4 allele status. This effect was more pronounced in older individuals, whereas higher A beta load appeared more closely related to epsilon4 in the younger age group (cut off point at the median age at death (72.5 years)). The -219 TT genotype was associated with a decrease in APOE expression. There was a 60% decrease in APOE expression in lymphocytes from probable Alzheimer cases v controls (p = 0.01). CONCLUSIONS: In the oldest individuals, reduced APOE expression, modulated in part by -219 G/T polymorphism, may influence risk and constitute a determinant A beta load in Alzheimer's disease.
Authors: C Berr; J C Lambert; V Sazdovitch; P Amouyel; M C Chartier-Harlin; M Mohr; N Heldt; M Kiesmann; J J Hauw Journal: Neurobiol Aging Date: 2001 Mar-Apr Impact factor: 4.673
Authors: J C Lambert; D Mann; L Goumidi; J Harris; P Amouyel; T Iwatsubo; C Lendon; M C Chartier-Harlin Journal: Lancet Date: 2001-02-24 Impact factor: 79.321
Authors: J C Lambert; T Brousseau; V Defosse; A Evans; D Arveiler; J B Ruidavets; B Haas; J P Cambou; G Luc; P Ducimetière; F Cambien; M C Chartier-Harlin; P Amouyel Journal: Hum Mol Genet Date: 2000-01-01 Impact factor: 6.150
Authors: L Zurutuza; P Verpillat; G Raux; D Hannequin; M Puel; S Belliard; A Michon; Y Pothin; A Camuzat; C Penet; C Martin; A Brice; D Campion; F Clerget-Darpoux; T Frebourg Journal: Eur J Hum Genet Date: 2000-09 Impact factor: 4.246
Authors: C Ramassamy; D Averill; U Beffert; L Theroux; S Lussier-Cacan; J S Cohn; Y Christen; A Schoofs; J Davignon; J Poirier Journal: Neurobiol Dis Date: 2000-02 Impact factor: 5.996
Authors: K Yamagata; K Urakami; K Ikeda; Y Ji; Y Adachi; H Arai; H Sasaki; K Sato; K Nakashima Journal: Dement Geriatr Cogn Disord Date: 2001 Mar-Apr Impact factor: 2.959
Authors: Michael Ewers; Giovanni B Frisoni; Stefan J Teipel; Lea T Grinberg; Edson Amaro; Helmut Heinsen; Paul M Thompson; Harald Hampel Journal: Prog Neurobiol Date: 2011-06-22 Impact factor: 11.685
Authors: Sterling C Johnson; Taylor W Schmitz; Mehul A Trivedi; Michele L Ries; Britta M Torgerson; Cynthia M Carlsson; Sanjay Asthana; Bruce P Hermann; Mark A Sager Journal: J Neurosci Date: 2006-05-31 Impact factor: 6.167
Authors: Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman Journal: N Engl J Med Date: 2009-07-16 Impact factor: 91.245
Authors: Bryan Maloney; Yuan-Wen Ge; Ronald C Petersen; John Hardy; Jack T Rogers; Jordi Pérez-Tur; Debomoy K Lahiri Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-01-05 Impact factor: 3.568